PAMU
SYRE icon

Pictet Asset Management (UK)’s Spyre Therapeutics SYRE Stock Holding History

Pictet Asset Management (UK)’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$17.6M Buy
101,312
+539
+0.5% +$97.9K 0.02% 552
2021
Q1 		$20M Hold
100,773
– – 0.02% 499
2020
Q4 		$19.8M Buy
100,773
+55,335
+122% +$11.5M 0.03% 482
2020
Q3 		$8.05M Buy
+45,438
New +$8.41M 0.01% 611

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pictet Asset Management (UK)'s SYRE Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Spyre Therapeutics (SYRE) stake by 0.53% in Q2 2021, buying an estimated $97.9K and bringing the position to 101,312 shares worth $17.6M. The position accounts for 0.02% of the portfolio, ranked #552.

Pictet Asset Management (UK) first reported a position in SYRE in Q3 2020 and has held it in 4 quarters since. The position peaked at $20M in Q1 2021. 78 funds tracked by Wall St. Rank hold SYRE as of Q2 2021.

  • Pictet Asset Management (UK) held 101,312 shares of Spyre Therapeutics worth $17.6M as of Q2 2021.
  • Pictet Asset Management (UK) bought 539 Spyre Therapeutics shares in Q2 2021, an estimated $97.9K.
  • Spyre Therapeutics made up 0.02% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #552 holding.
  • Pictet Asset Management (UK) first reported a position in Spyre Therapeutics in Q3 2020 and has held it in 4 quarters since.
  • Pictet Asset Management (UK)'s Spyre Therapeutics position peaked at $20M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.